Objective:To analyze the characteristics of Fournier gangrene (FG) induced by sodium-glucose cotransporter 2 inhibitors (SGLT2i), and provide reference for clinical safe drug use.Methods:CNKI, Wanfang Med Online, VIP, PubMed, Web of Science and other databases (up to January 2024) were retrieved and clinical data on patients with FG associated with the 5 kinds of SGLT2i currently used in clinical practice in China were collected and descriptively analyzed, including gender, age, comorbidities, concomitant medications, onset time and clinical manifestations of SGLT2i-related FG, laboratory and imaging examination results, treatment and outcomes, etc.Results:A total of 15 documents were included in the analysis, involving 15 patients, with 12 males and 3 females. The age of these patients ranged from 34 to 72 years, with 11 cases being over 50 years. Dapagliflozin was used in 7 cases, empagliflozin in 6 cases, canagliflozin in 2 cases, and no related reports on ertugliflozin and henagliflozin were collected. The main clinical manifestations of the 15 patients were redness, swelling, pain, abscess or purulent discharge in perineum, scrotum and perianal, etc. The time from application of SGLT2i to onset of FG ranged from 1 month to 6 years. Wound secretion bacterial culture was performed in 10 patients, and the results were all positive, including 9 cases of bacterial infection and 1 case of mixed infection of bacteria and fungi. All 13 patients who underwent imaging examinations had imaging manifestations related to FG. SGLT2i were discontinued in all patients. After treatments with broad-spectrum antibiotics and surgery, 14 cases were improved and 1 case was cured.Conclusions:SGLT2i has the risk of causing FG, which is more common in males. The clinical use of SGLT2i should be monitored closely. Secretion culture and imaging examination are helpful for the diagnosis of FG. The patient′s prognosis is good after discontinuation of medication, symptomatic treatment, and surgery.

Objective:To investigate the application value of changes in T/QRS ratio (?T/QRS) in predicting risk stratification for high-risk non-ST-elevation myocardial infarction (NSTEMI).Methods:A total of 158 patients with NSTEMI who received treatment at the Department of Cardiology, Baoji High-tech Hospital, from February 2022 to February 2024 were included in this study. Based on the global registry of acute coronary events score, the enrolled patients with NSTEMI were divided into low-, medium-, and high-risk groups. Baseline data and clinical examination results were collected for all patients, and the clinical outcomes of patients with NSTEMI in different risk stratification groups were compared and analyzed. Spearman correlation analysis was performed to assess the correlation between ?T/QRS and the global registry of acute coronary events score in patients with NSTEMI. Logistic regression analysis was conducted to identify risk factors that influence the severity of NSTEMI. The predictive value of ?T/QRS for high-risk NSTEMI in patients was evaluated using the receiver operating characteristic curve.Results:In patients with NSTEMI from the low-risk, medium-risk, and high-risk groups, the values of ?T/QRS in the inferior and lateral leads increased sequentially [(1.01 ± 0.25) vs. (1.32 ± 0.19) vs. (1.74 ± 0.21), F = 6.10, P < 0.001; (1.01 ± 0.13) vs. (1.36 ± 0.11) vs. (1.66 ± 0.05), F = 5.73, P < 0.001]. Spearman correlation analysis demonstrated a positive correlation between ?T/QRS in the inferior and lateral leads and the global registry of acute coronary events score in patients with NSTEMI ( r = 0.73, P < 0.001; r = 0.78, P < 0.001). Logistic regression analysis revealed that elevated ?T/QRS values in the inferior and lateral leads were risk factors for high-risk NSTEMI, with odds ratios of 10.361 and 10.738, respectively. Receiver operating characteristic curve analysis indicated that the area under the curve for predicting high-risk NSTEMI patients using ?T/QRS in the inferior and lateral leads was 0.932 and 0.855, respectively. Conclusions:?T/QRS in the inferior and lateral leads are associated with risk stratification in patients with NSTEMI and can effectively predict high-risk NSTEMI, suggesting a promising clinical application.

Objective:To investigate the application value of changes in T/QRS ratio (?T/QRS) in predicting risk stratification for high-risk non-ST-elevation myocardial infarction (NSTEMI).Methods:A total of 158 patients with NSTEMI who received treatment at the Department of Cardiology, Baoji High-tech Hospital, from February 2022 to February 2024 were included in this study. Based on the global registry of acute coronary events score, the enrolled patients with NSTEMI were divided into low-, medium-, and high-risk groups. Baseline data and clinical examination results were collected for all patients, and the clinical outcomes of patients with NSTEMI in different risk stratification groups were compared and analyzed. Spearman correlation analysis was performed to assess the correlation between ?T/QRS and the global registry of acute coronary events score in patients with NSTEMI. Logistic regression analysis was conducted to identify risk factors that influence the severity of NSTEMI. The predictive value of ?T/QRS for high-risk NSTEMI in patients was evaluated using the receiver operating characteristic curve.Results:In patients with NSTEMI from the low-risk, medium-risk, and high-risk groups, the values of ?T/QRS in the inferior and lateral leads increased sequentially [(1.01 ± 0.25) vs. (1.32 ± 0.19) vs. (1.74 ± 0.21), F = 6.10, P < 0.001; (1.01 ± 0.13) vs. (1.36 ± 0.11) vs. (1.66 ± 0.05), F = 5.73, P < 0.001]. Spearman correlation analysis demonstrated a positive correlation between ?T/QRS in the inferior and lateral leads and the global registry of acute coronary events score in patients with NSTEMI ( r = 0.73, P < 0.001; r = 0.78, P < 0.001). Logistic regression analysis revealed that elevated ?T/QRS values in the inferior and lateral leads were risk factors for high-risk NSTEMI, with odds ratios of 10.361 and 10.738, respectively. Receiver operating characteristic curve analysis indicated that the area under the curve for predicting high-risk NSTEMI patients using ?T/QRS in the inferior and lateral leads was 0.932 and 0.855, respectively. Conclusions:?T/QRS in the inferior and lateral leads are associated with risk stratification in patients with NSTEMI and can effectively predict high-risk NSTEMI, suggesting a promising clinical application.

Objective:To analyze the characteristics of Fournier gangrene (FG) induced by sodium-glucose cotransporter 2 inhibitors (SGLT2i), and provide reference for clinical safe drug use.Methods:CNKI, Wanfang Med Online, VIP, PubMed, Web of Science and other databases (up to January 2024) were retrieved and clinical data on patients with FG associated with the 5 kinds of SGLT2i currently used in clinical practice in China were collected and descriptively analyzed, including gender, age, comorbidities, concomitant medications, onset time and clinical manifestations of SGLT2i-related FG, laboratory and imaging examination results, treatment and outcomes, etc.Results:A total of 15 documents were included in the analysis, involving 15 patients, with 12 males and 3 females. The age of these patients ranged from 34 to 72 years, with 11 cases being over 50 years. Dapagliflozin was used in 7 cases, empagliflozin in 6 cases, canagliflozin in 2 cases, and no related reports on ertugliflozin and henagliflozin were collected. The main clinical manifestations of the 15 patients were redness, swelling, pain, abscess or purulent discharge in perineum, scrotum and perianal, etc. The time from application of SGLT2i to onset of FG ranged from 1 month to 6 years. Wound secretion bacterial culture was performed in 10 patients, and the results were all positive, including 9 cases of bacterial infection and 1 case of mixed infection of bacteria and fungi. All 13 patients who underwent imaging examinations had imaging manifestations related to FG. SGLT2i were discontinued in all patients. After treatments with broad-spectrum antibiotics and surgery, 14 cases were improved and 1 case was cured.Conclusions:SGLT2i has the risk of causing FG, which is more common in males. The clinical use of SGLT2i should be monitored closely. Secretion culture and imaging examination are helpful for the diagnosis of FG. The patient′s prognosis is good after discontinuation of medication, symptomatic treatment, and surgery.

Objective:To investigate the experience of body quality management in overweight or obese patients with breast cancer during chemotherapy, and to provide reference for formulating targeted nursing interventions.Methods:This study was a phenomenological study of qualitative research. Objective selected 10 obese patients with breast cancer from breast surgery of Provincial Hospital Affiliated to Shandong First Medical University and the First Affiliated Hospital of Shandong First Medical University to conduct semi-structured interviews during chemotherapy from March to May 2023. Colaizzi 7-step analysis method was used to sort out and analyze the data and extract the theme.Results:The average age of 10 overweight or obese breast cancer patients was 43.2 years. Three themes and eight subthemes were extracted, including insufficient motivation of body quality management (insufficient cognition, insufficient drive, insufficient motivation), disturbing experience of body quality management (uncertainty of disease, symptom distress during chemotherapy, inability to identify the correctness of information), regulation and support of body quality management (mastering correct methods of body quality regulation and support in all aspects).Conclusions:The motivation of body quality management in overweight or obese patients with breast cancer during chemotherapy is insufficient and there are many problems. Medical staff can take effective measures from clarifying the significance of body quality management, providing targeted information support, establishing a good social support system and providing effective body quality management guidance, so as to improve the effectiveness of body quality management in obese patients with breast cancer during chemotherapy.

OBJECTIVE To explore the characteristics of adverse drug reaction （ADR） induced by semaglutide and provide a reference for clinically safe medication. METHODS Using search terms such as “semaglutide” and “adverse reactions” in both Chinese and English， the case reports about ADRs caused by semaglutide were searched and analyzed from PubMed， Web of Science， SpringerLink， CNKI， Chinese Medical Journal Full-text Database， Wanfang Medical Network and VMIS. RESULTS Overall 14 literature were included， involving 17 patients. Among 17 patients， 9 were female and 8 were male， with the age ranging from 25 to 80 years. Eight patients were given two or more drugs， and eight patients took 0.25 mg as the initial dose； the ADR occurred most frequently within 6 months （94.12%）. Sixteen patients’ symptoms improved or recovered after drug withdrawal and symptomatic treatment. Eleven patients did not mention whether to continue to use semaglutide in the future. Nine patients underwent ADR correlation evaluation， and 1， 3， 1 and 4 cases were determined to be “definite”，“ probable”，“ possible”， and “doubtful” respectively. Semaglutide-induced ADRs involved multiple organs or systems， most of which were the digestive system （35.29%）， followed by skin tissue （29.41%）. Among them， acute gastric dilation， severe liver injury， calculous cholecystitis， bullous pemphigoid， eosinophilic fasciitis， acute kidney injury， acute interstitial nephritis， depression and acute hemolytic anemia were not mentioned in the instruction. CONCLUSIONS ADRs caused by semaglutide can occur in all ages， mainly within 6 months after medication， and mainly involve the digestive system， skin tissue， etc. Great attention should be paid to pharmaceutical care for those patients with liver and kidney dysfunction， neuropsychiatric diseases， glucose-6-phosphate dehydrogenase deficiency， etc. When ADR occurs， drug withdrawal and symptomatic treatment should be performed promptly to ensure patients’ medication safety.

As the first domestically originated cell cycle protein-dependent kinase 4/6 inhibitor,dalpiciclib has been approved by the State Drug Ad-ministration for the treatment of hormone recep-tor-positive/human epidermal growth factor recep-tor 2-negative advanced or metastatic breast can-cer in combination with fulvestrant or aromatase inhibitors.This article focuses on the progress of dalpiciclib research in breast cancer,summarizing the drug's mechanism of action,phase Ⅰ-Ⅲ clinical trials,and drug safety issues.

Drug conditional approval refers to the accelerated approval and marketing of clinically urgently needed drugs with outstanding therapeutic value through the form of "approval first, verification later" before completing complete clinical trials. Since the 1990s, the United States, Canada, the European Union, Japan, Australia, and the United Kingdom have successively implemented drug conditional approval for marketing. In 2017, the application for conditional approval of drugs was implemented in China. In this paper, the pre-market conditions and requirements, post-market monitoring and supervision of drugs in China are compared with other countries/regions. Based on the comparison results, the possible optimization directions of China′s drug conditional approval system are summarized and explored.

Drug conditional approval refers to the accelerated approval and marketing of clinically urgently needed drugs with outstanding therapeutic value through the form of "approval first, verification later" before completing complete clinical trials. Since the 1990s, the United States, Canada, the European Union, Japan, Australia, and the United Kingdom have successively implemented drug conditional approval for marketing. In 2017, the application for conditional approval of drugs was implemented in China. In this paper, the pre-market conditions and requirements, post-market monitoring and supervision of drugs in China are compared with other countries/regions. Based on the comparison results, the possible optimization directions of China′s drug conditional approval system are summarized and explored.

Objective:To understand the cognition and practice of nurses in anesthesia and resuscitation room on patients with xerostomia after general anesthesia, and to provide reference for improving xerostomia.Methods:This was a phenomenological research methods in qualitative research. From January to March 2021, the purpose of sampling method was used to select 10 nurses in anesthesia and recovery rooms from 3 grade A tertiary hospitals in Jinan City, Shandong Province as the research objects. The 7-step Colaizzi analysis method was used to analyze the data and refines the themes.Results:A total of 2 themes and 8 sub-themes were extracted: cognition of the practice process of patients with xerostomia (high recognition and affirmation, support for patients to participate in xerostomia management, focus on children with xerostomia), obstructive factors during practice of patients(intensive nursing human resources, lack of practice atmosphere, lack of standardized assessment tools, incomplete management measures, insufficient nurses′ self-efficacy).Conclusions:Nurses in anesthesia and resuscitation room play a guiding role in the management of patients with xerostomia after general anesthesia. It is necessary to understand nurses′ cognition of xerostomia and the factors that affect their practical behavior in order to supply reference to formulate scientific and systematic management system for xerostomia patients.